Discovery and Evaluation of Imidazo[2,1- b ][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Qi Zeng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P.R. China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, alpha-Synuclein, Thiadiazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects.
Abstract (Originalsprache)
α-synuclein (α-syn) pathologies are central to the development of synucleinopathies including Parkinson's disease (PD). Positron emission tomography (PET) imaging of α-syn pathologies is one strategy to facilitate the diagnosis, understanding, and treatment of synucleinopathies, but has been restricted by the lack of specific α-syn PET probes. In this work, we identified 2,6-disubstituted imidazo[2,1-b][1,3,4]thiadiazole (ITA) as a new α-syn-binding scaffold. Through autoradiography studies, we discovered an iodinated lead compound [125I]ITA-3, with moderate binding affinity (IC50 = 55 nM) to α-syn pathologies in human PD brain sections. Modified from [125I]ITA-3, we developed a potential PET tracer, [18F]FITA-2 (radiochemical yield >25%, molar activity >110 GBq/μmol), which demonstrated clear signals in α-syn-rich regions in human PD brain tissues (IC50 = 245 nM), good brain uptake (SUVpeak = 2.80 ± 0.45), and fast clearance rate in rats. Overall, [18F]FITA-2 appears to be a promising candidate for α-syn PET imaging and merits further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P.R. China.
- Nuclear Medicine Department, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, P.R. China.
- Department of Anatomy and Neurobiology, Central South University Xiangya School of Medicine, Changsha 410013, P.R. China.
- Wuhan Institute for Neuroscience and Neuroengineering, South-Central Minzu University, Wuhan 430074, P.R. China.
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, P.R. China.
- Beijing Hesu Pharmaceuticals Inc., Beijing 101500, China.
ORCID-Profile: Jiapei Dai, Yu Liu, Mengchao Cui
Förderung
- National Natural Science Foundation of China
- Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects
Zitieren
APA
Zeng, Q., Zhang, X., Li, Y., Zhang, Q., Dai, J., Yan, X. X., Liu, Y., Zhang, J., Liu, S., & Cui, M. (2024). Discovery and Evaluation of Imidazo[2,1- b ][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00686
Vancouver
Zeng Q, Zhang X, Li Y, Zhang Q, Dai J, Yan XX, et al. Discovery and Evaluation of Imidazo[2,1- b ][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00686
BibTeX
@article{Zeng2024,
author = {Zeng, Qi and Zhang, Xiaojun and Li, Yuying and Zhang, Qilei and Dai, Jiapei and Yan, Xiao-Xin and Liu, Yu and Zhang, Jinming and Liu, Sen and Cui, Mengchao},
title = {Discovery and Evaluation of Imidazo[2,1- b ][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00686}
}
EUVIMED